Literature DB >> 7023743

The randomized clinical trial: bias in analysis.

G S May, D L DeMets, L M Friedman, C Furberg, E Passamani.   

Abstract

The realization that bias in patient selection may influence the results of clinical studies has helped to establish the randomized controlled clinical trial in medical research. However, bias can be equally important at other stages of a trial, especially at the time of analysis. Withdrawing patients from consideration in the analysis because of ineligibility on account of study entry criteria, lack of compliance to the protocol, or data of poor quality may be a source of systematic error. Examples to illustrate the possible consequences are taken from trials in the cardiovascular field. We recommended that reported study results should include outcome data from all subjects randomized in the group to which they were originally assigned.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023743     DOI: 10.1161/01.cir.64.4.669

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  Systematic reviews in health care: Assessing the quality of controlled clinical trials.

Authors:  P Jüni; D G Altman; M Egger
Journal:  BMJ       Date:  2001-07-07

2.  Statistics and ethics in medical research.

Authors:  David L DeMets
Journal:  Sci Eng Ethics       Date:  1999-01       Impact factor: 3.525

3.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

4.  Clinical characteristics and current management of medically refractory unstable angina.

Authors:  J S Rankin; J R Newton; R M Califf; R H Jones; A S Wechsler; H N Oldham; W G Wolfe; J E Lowe
Journal:  Ann Surg       Date:  1984-10       Impact factor: 12.969

5.  Dexamethasone treatment for acute bacterial meningitis: how strong is the evidence for routine use?

Authors:  K Prasad; T Haines
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

Review 6.  Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer.

Authors:  Diana Lüftner; Andreas D Hartkopf; Michael P Lux; Friedrich Overkamp; Hans Tesch; Adriana Titzmann; Patrik Pöschke; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Wolfgang Janni; Tanja N Fehm; Hans-Christian Kolberg; Johannes Ettl; Diethelm Wallwiener; Andreas Schneeweiss; Sara Y Brucker; Peter A Fasching
Journal:  Breast Care (Basel)       Date:  2021-03-16       Impact factor: 2.860

7.  Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database.

Authors:  Moutaz El Kadri; Ahmed Ghorab; Jean Joury; Mohamed Farghaly; Nancy Awad; Badarinath Chickballapur Ramachandrachar; Ashok Natarajan
Journal:  Avicenna J Med       Date:  2021-04-19

8.  Evaluating the quality of randomized controlled trials that examine the efficacy of natural health products: a systematic review of critical appraisal instruments.

Authors:  Anne Marie Whelan; Tannis M Jurgens; Lindsay Lord
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-18       Impact factor: 2.629

9.  A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in Niger.

Authors:  Abdou Amza; Boubacar Kadri; Baido Nassirou; Nicole E Stoller; Sun N Yu; Zhaoxia Zhou; Sheila K West; David C W Mabey; Robin L Bailey; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Bruce D Gaynor
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

10.  Development and evaluation of an instrument for the critical appraisal of randomized controlled trials of natural products.

Authors:  Tannis Jurgens; Anne Marie Whelan; Melissa MacDonald; Lindsay Lord
Journal:  BMC Complement Altern Med       Date:  2009-04-23       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.